



# Consolidated Financial Result Briefing for the three months ended June 30, 2025

**CYBERDYNE Inc.** (Ticker Code: 7779)

August 14, 2025

# 1Q FY2025 - Consolidated Results Summary (IFRS)

Consolidated revenue decreased due to factors such as the sale of a subsidiary in the previous fiscal year, while operating profit improved.

Profit before tax and net profit turned positive, mainly due to gains on the valuation of investment securities.

(Millions of yen)	2024/1Q	2025/1Q	YoY	%
Revenue	1,155	1,000	-156	-13%
Operating profit (loss)	(154)	(100)	+54	-
Profit (loss) before tax	(7)	433	+440	-
Profit (loss) attributable to owners of parent	11	251	+240	-

Revenue

1,000 Million  
YoY -156 Million (-13%)

- EMEA product rentals: +86 million yen (business +89 million yen, forex -2 million yen)
- Domestic & APAC product rentals, etc.: +43 million yen (business +52 million yen, forex -9 million yen)
- Treatment services: -114 million yen (business -90 million yen, forex -23 million yen)
- New business expansion: LeyLine -139 million yen, domestic -32 million yen

Operating profit (loss)

-100 Million  
YoY +54 Million

- EMEA product rentals: +75 million yen (business +78 million yen, forex -3 million yen)
- Domestic & APAC product rentals, etc.: +27 million yen (business +33 million yen, forex -6 million yen)
- Treatment services: -20 million yen (business -21 million yen, forex +1 million yen)
- New business expansion: LeyLine +22 million yen, domestic +10 million yen
- R&D and head office expenses, etc.: -61 million yen

Profit (loss) before tax

433 Million  
YoY +440 Million

- Operating profit variance: +54 million yen
- Gain on valuation of investment securities: +451 million yen  
(Q1 FY2025: +454 million yen vs. Q1 FY2024: +3 million yen)
- Financial income/expenses and others: -65 million yen

※ Exchange Rate USD/JPY: Mar 149.52 → Jun 144.81 (YoY: Mar 151.41 → Jun 161.07)  
EUR/JPY: Mar 162.08 → Jun 169.66 (YoY: Mar 163.24 → Jun 172.33)

# Consolidated results: Revenue / Operating profit (Margin)

Product rentals and related services recorded year-on-year increases in both revenue and profit, with growth in EMEA (primarily Germany), APAC (primarily Malaysia), and Japan.

Treatment services experienced declines in both revenue and profit, partly due to a temporary impact from the change in the management structure of RHG in the U.S. at the beginning of the fiscal year.

New business expansion recorded a decrease in revenue but an increase in profit, due to the sale of LeyLine at the end of the previous fiscal year.

(Millions of yen)		2024/1Q	2025/1Q	YoY	%
Product rental	Revenue Operating Profit (Margin %)	408 170 (42%)	537 272 (51%)	+129 +102 (+9pt)	+32% +60%
Treatment service	Revenue Operating Profit (Margin %)	523 -17 (-3%)	409 -38 (-9%)	-114 -21 (-6pt)	-22% -
New business expansion	Revenue Operating Profit (Margin %)	224 -33 (-15%)	53 - 0 (-1%)	-171 +32 (+14pt)	-76% -
R&D expenses & Head office expenses	Adjusted amount	-273	-334	-61	-
Consolidated total (IFRS)	Revenue Operating Profit (Margin %)	1,155 -154 (-13%)	1,000 -100 (-10%)	-156 +53 (+3pt)	-13% -

※1 Amount of profit or loss, which is revenue minus operating expenses, for each business

※2 Adjustment amount of R&D expenses, head office administrative expenses, other income and expenses, etc.

- Product rental : Revenue from rental of the Group's products (includes revenue from sales)
- Treatment service : Revenue from treatment services provided through the Group's facilities (including service fees in Robocare Centers)
- New business expansion : Revenue from the Group's new business (e.g. subsidiary in Mobility and Sleeping App)

# Revenue from rental and sales (by product)

(Millions of yen) 2025/1Q (2024/1Q)	Japan	EMEA	APAC	AMER	Total	YoY
Product rental	246 (223)	148 (61)	135 (114)	9 (10)	537 (408)	+129 (+32%)
Treatment Service	32 (31)	12 (9)	-	365 (482)	409 (523)	-114 (-22%)
New business Expansion	53 (85)	- (139)	-	-	53 (224)	-171 (-76%)
Total	331 (340)	159 (209)	135 (114)	374 (492)	1,000 (1,155)	-156 (-13%)
YoY	-9 (-3%)	-50 (-24%)	+20 (+18%)	-118 (-24%)		
	Domestic	Foreign				
Sales Revenue ratio	33%	67%			100%	

EMEA : Europe, the Middle East and Africa

APAC : Asia-Pacific \*Excluding Japan

AMER : North, Central and South America



# Revenue from rental and sales (by product)

Domestic sales increased mainly due to new installations of the Medical HAL Lower Limb Type.

Overseas sales increased mainly due to new installations in EMEA (primarily Germany) and APAC (primarily Malaysia).

(Millions of yen) 2025/1Q (2024/1Q)	Type of product	In Japan	Outside Japan	Total
Cybernetics Treatment  Functional improvement and regeneration	Medical HAL Lower Limb Type	103 (87)	232 (129)	334 (215)
	Non-medical HAL Lower Limb Type	37 (42)	-	37 (42)
	HAL Single Joint Type	24 (22)	35 (26)	58 (48)
Well-being and care	HAL Lumbar Type	19 (25)	22 (21)	41 (46)
Labor Support	HAL Lumbar Type	8 (9)	-	8 (9)
	Mobile robot (CL02 etc.)	35 (13)	-	35 (13)
Other (Acoustic X、 Other products)		19 (25)	3 (10)	23 (35)
Total		245 (223)	291 (186)	537 (408)

# Disclaimer

This presentation contains forward-looking statements concerning CYBERDYNE, Inc. and its Group's future plans, strategies and performance. Forward-looking statements contained in this presentation are based on information currently available and on certain assumption redeemed rational at the time of creation of this presentation. As such, due to various risks and uncertainties, the statements and assumption does not guarantee future performance, may be considered differently from alternative perspectives and may differ from the actual result.

Further, this presentation contains statements and information regarding corporate entities other than those belonging to the CYBERDYNE group, which have been complied from various publicly- available sources. CYBERDYNE does not verify nor guarantees accuracy and appropriateness of those information.



***CYBERDYNE***